Design Therapeutics (DSGN) Other Non-Current Liabilities (2020 - 2021)
Design Therapeutics (DSGN) posted quarterly Other Non-Current Liabilities of $11000.0 for Q3 2021, down 92.14% on a QoQ basis from $140000.0 in Q2 2021.
Design Therapeutics (DSGN) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Design Therapeutics has reported Other Non-Current Liabilities for 2 years, with the latest figure at $11000.0 in Q3 2021.
- Other Non-Current Liabilities for Q3 2021 came in at $11000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $11000.0 (changed N/A YoY), and the FY2020 annual result was $145000.0, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $11000.0 in Q3 2021, from $140000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $145000.0 in Q4 2020 and troughed at $11000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 140,000.00 |
| Mar 31, 2021 | 142,000.00 |
| Dec 31, 2020 | 145,000.00 |